This is the new drug, in case the world is involved in nuclear war.

Inside each one is an experimental dose of PLXR-18, a drug developing for a nuclear disaster.

It is designed to help the body recover after radiation exposure should a nuclear weapon explode.

Now, the Defense Department tests this drug to see if it can be managed before service members are exposed to radiation.

The test of what North Korea claimed to be a hydrogen bomb has led researchers to rush into the case. The Na (Inaudiable) Armed Forces, the first respondents to any radiation event, reported “CNN” Transmission Periscope.

And one of the main goals is to see if we can use cells to treat the soldier in a profile treatment before we expose ourselves to radiation and prevent the damage that is the result of radiation.

Fukushima, home to a 2011 nuclear attack, has become an opportunity for Plustemin.

A medical university has collaborated with the Israeli company in developing this drug.

PLXR 18 is made up of placenta cells reported to fit in on all doses and is easier to accumulate.

Before we go to the lab where the cells produce, because it's a clean room, we need to extend these sterile suits to make sure we don't sink the environment with bacteria.

Within the labs, these libraries multiply possible cells and doses. Radiation attacks the body in part by destroying the bone marrow, which produces critical blood cells.

Destroying bone marrow, which helps restore bone marrow. How many cells first enter? And how many cells come out seven to eight days later? So about 600 million cells first. And after about a week, you get about 20 billion cells./Periscopi/